您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8405 处方药 8032 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国际免费电话:
QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 心血管系统药物->抗高血压药物
处方药:处方药
包装规格: 10小瓶/批
计价单位:
  点击放大  
生产厂家英文名:
American Regent, Inc.
该药品相关信息网址1:
https://www.healthline.com/health/torsemide-oral-tablet
该药品相关信息网址2:
https://www.medicinenet.com/torsemide-oral/article.htm
原产地英文商品名:
Torsemide 50mg/5 ml, 5ml/vial
原产地英文药品名:
TORSEMIDE
中文参考商品译名:
托拉塞米 50毫克/5毫升, 5毫升/小瓶
中文参考药品译名:
TORSEMIDE
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Acute renal failure
英文适应病症2:
Chronic renal failure
临床试验期:
完成
中文适应病症参考翻译1:
急性肾衰
中文适应病症参考翻译2:
慢性肾衰
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201883007470633.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文Torsemide处方资料(仅供参考)

中文通用名称: 托拉塞米

英文通用名称: Torasemide

其 它 名 称: Torsemide,Demadex,托拉塞米注射液,托拉塞米片,Torasemide Capsules,Torasemide Injection,Torasemide Tablets,托拉塞米胶囊,注射用托拉塞米,Unat,特苏尼,拓赛,伊迈格,益耐,Torsaemide For Injection,特苏平,维达通,优利德,特苏力,丽泉,丽芝,特苏敏,泽通

产 品 分 类: 西药\肾/泌尿系统用药\利尿药与脱水药\利尿药\袢利尿药

药理作用 demadex (torsemid  

本品为强效利尿剂,作用机理与速尿相似,主要作用于肾髓袢升支粗段,抑制Cl- 的主动重吸收,使髓袢升支NaCl的重吸收减少,肾髓质渗透压降低,管腔内渗透压增大,干扰尿的浓缩过程,与其它髓袢利尿药不同的是,本品对近端小管部位无作用,因而不会造成 K+ 的排出增加。

药动学

口服本品1小时后,达到血浆峰浓度,其中有1/4到达尿液。由于它具有与其它髓袢利尿剂相同的化学特性和蛋白亲和力,因而具有与其他髓袢利尿药相似的分布容积,约为0.09~0.31L/kg,平均为0.16L/kg;清除率为0.33~1.1ml/min•kg,平均值为0.6ml/min•kg,其非肾清除约4倍于肾清除;半衰期0.8~6.0小时,平均为3.3小时,为目前该类利尿剂中最长者,半衰期长意味着药物在小管系统中保持高浓度时间长,因而就有较多的药物分泌到尿液,到达作用部位,产生较长的作用时间。

适应症

急性肾衰,慢性肾衰及原发性高血压。

1.用于急性肾衰和慢性肾衰:理想的治疗急性肾衰药物应具有如下特点:

①增加肾容积和钠排泄具有剂量依耐性,即使肾小球滤过率低于5ml/min。

②不影响钙和钾的排泄。

③其排泄与代谢状况与肾功能无关。

④即使大剂量使用也无毒副作用。

在对比实验中,重度肾衰病人分别静脉给予单剂量速尿(100、200mg)和本品(100、200mg)。四种剂量在24小时内明显引起累积尿量、钠和氯的排出增加。TS在肾衰病人的血浆和尿中半衰期与健康人比较没有区别,而服用速尿病人则有所延长。速尿和TS在肾衰病人中肾清除率均降低,但TS总清除率没有变化(Kult等1990)。药物的利尿作用取决于到达髓袢升支原形药物及其代谢产物数量。钙的排泄及血管紧张素肽原酶活性的在速尿治疗中明显增高,而TS治疗组没有变化。TS没有观察到毒付作用,特别是不损伤耳蜗功能,大剂量TS用于重度慢性肾衰也是安全、有效的。

2.用于高血压:

1990年 Russo等人对11例高血压和慢性肾炎病人进行研究,给予TS 200mg/d,明显降低血压、减轻周围水肿,总有效率达100%,且无任何不良反应。

用法用量  

1.用于慢性肾衰,100~200mg/d,口服或静注。

2.治疗原发性高血压,2.5~5mg/次,日服一次。

不良反应

  无严重不良反应,常见的不良反应为头痛、头晕、虚弱、恶心、肌肉痉挛。

孕妇及哺乳期妇女用药

不推荐怀孕期和哺乳期的妇女使用本品。

儿童用药

对儿童患者是否安全有效尚不明确。

老年患者用药

老年患者使用本品的疗效和安全性与年轻人无区别,但老年患者使用本品初期尤其需注意监测血压、电解质及有无排尿困难。

注意事项

1、使用本品者应定期检查电解质(特别是血钾)、血糖、尿酸、肌酐、血脂等。

2、本品开始治疗前排尿障碍必须被纠正,特别对老年病人或治疗刚开始时要仔细监察电解质和血容量的不足和血液浓缩的有关症状。

3、肝硬化腹水患者应用本品进行利尿时,应住院进行治疗,这些病人如利尿过快,可造成严重的电解质紊乱和肝昏迷。

4、本品与醛固酮拮抗剂或与保钾药物一起使用可防止低钾血症和代谢性碱中毒。

5、前列腺肥大的患者排尿困难,使用本品尿量增多可导致尿潴留和膀胱扩张。

6、在刚开始用本品治疗或由其他药物转为使用本品治疗或开始一种新的辅助药物治疗时,个别患者警觉状态受到影响(如在驾驶车辆或操作机器时)。

7、本品必须缓慢静脉注射,本品不应与其他药物混合后静脉注射,但可根据需要用生理盐水或5%葡萄糖溶液稀释。

8、如需长期用药建议尽早从静脉给药转为口服用药,静脉给药疗程限于一周。

禁忌

肾功能衰竭无尿患者,肝昏迷前期或肝昏迷患者,对本品或磺酰脲类过敏患者,低血压、低血容量、低钾或低钠血症患者,严重排尿困难(如前列腺肥大)患者禁用本品。

Chinese common name: Torasemi

English common name: Torasemide

Other names: Torsemide, Demadex, Torasemide, Torasemide, Torasemide Capsules, Torasemide Injection, Torasemide Tablets, Torasemi Capsules, Torasemide for Injection, Unat, Tesuni ,Texay,Imag,Yi Nai,Torsaemide For Injection,Tesupin,Vidatong,Uli De,Tsuuli,Liquan,Lizhi,Tesumin,Zetong

Product Classification: Western medicine\Kidney/urinary system medications\Diuretics and dehydration drugs\Diuretics\袢 Diuretics

Pharmacological action demadex (torsemid

This product is a powerful diuretic. The mechanism of action is similar to that of furosemide. It mainly acts on the thick segment of the ascending branch of the renal pulp, inhibits the active reabsorption of Cl-, and reduces the reabsorption of NaCl in the ascending branch. The osmotic pressure is reduced, the osmotic pressure in the lumen is increased, and the urinary concentration process is disturbed. Unlike other medullary diuretics, this product has no effect on the proximal tubules and thus does not cause an increase in K+ excretion.

Pharmacokinetics

One hour after oral administration of this product, a peak plasma concentration was reached, of which 1/4 reached the urine. Because it has the same chemical properties and protein affinity as other medullary diuretics, it has a similar volume of distribution to other medullary diuretics, about 0.09 ~ 0.31L / kg, an average of 0.16L / kg; clearance rate of 0.33 ~1.1ml/min•kg, with an average of 0.6ml/min•kg, which is about 4 times more than renal clearance in non-renal clearance; the half-life is 0.8-6.0 hours, with an average of 3.3 hours, which is the longest of the current diuretics. Long half-life means that the drug remains in the small tube system for a long time, so that more drugs are secreted into the urine and reach the site of action, resulting in a longer duration of action.

Indications

Acute renal failure, chronic renal failure and essential hypertension.

1. For acute renal failure and chronic renal failure: the ideal treatment for acute renal failure should have the following characteristics:

1 increase renal volume and sodium excretion with dose tolerance, even if the glomerular filtration rate is less than 5ml /min.

2 does not affect the excretion of calcium and potassium.

3 Its excretion and metabolic status are not related to renal function.

4 No toxic side effects even in large doses.

In the comparative experiment, patients with severe renal failure were given a single dose of furosemide (100, 200 mg) and this product (100, 200 mg). The four doses apparently caused an increase in cumulative urine volume, sodium and chlorine excretion within 24 hours. The plasma and urinary half-life of TS in patients with renal failure is no different from that of healthy people, while patients taking furosemide have been prolonged. Furosemide and TS have decreased renal clearance in patients with renal failure, but there is no change in total TS clearance (Kult et al 1990). The diuretic effect of the drug depends on the amount of the protoplast and its metabolites reaching the myelin. Calcium excretion and angiotensinogenase activity were significantly increased in furosemide treatment, whereas there was no change in the TS treatment group. TS did not observe the toxicity, especially the cochlear function, and high-dose TS was safe and effective for severe chronic renal failure.

2. For high blood pressure:

In 1990, Russo et al. studied 11 patients with hypertension and chronic nephritis, and given TS 200mg/d, which significantly reduced blood pressure and reduced peripheral edema. The total effective rate was 100% without any adverse reactions.

Usage and Usage

1. For chronic renal failure, 100 ~ 200mg / d, oral or intravenous.

2. Treatment of essential hypertension, 2.5 ~ 5mg / time, once a day.

 

Adverse reactions

No serious adverse reactions, common adverse reactions are headache, dizziness, weakness, nausea, muscle spasm.

Pregnant women and lactating women

This product is not recommended for women during pregnancy and lactation.

Child medication

It is not clear whether children are safe and effective.

Medicine for elderly patients

The efficacy and safety of this product in elderly patients is no different from that of young people, but elderly patients need to pay attention to monitoring blood pressure, electrolytes and dysuria in the initial stage of using this product.

Notes

1. Use this product regularly to check electrolytes (especially blood potassium), blood sugar, uric acid, creatinine, and blood lipids.

2, urinary dysfunction before the start of treatment of this product must be corrected, especially for elderly patients or treatment at the beginning to carefully monitor the electrolyte and blood volume deficiency and blood concentration related symptoms.

3, patients with cirrhosis ascites when using this product for diuretic, should be hospitalized for treatment, these patients such as diuretic too fast, can cause serious electrolyte imbalance and hepatic coma.

4, this product and aldosterone antagonist or with potassium-preserving drugs can prevent hypokalemia and metabolic alkalosis.

5, patients with prostatic hypertrophy dysuria, the use of this product increased urine volume can lead to urinary retention and bladder expansion.

6. Individual patient alertness is affected (such as when driving a vehicle or operating a machine) at the beginning of treatment with this product or when switching from other drugs to this product or when starting a new adjuvant therapy.

7, this product must be slowly intravenously injected, this product should not be mixed with other drugs after intravenous injection, but can be diluted with physiological saline or 5% glucose solution as needed.

8. If long-term medication is required, it is recommended to switch from intravenous to oral administration as soon as possible. The intravenous administration is limited to one week.

Contraindications

Neurature failure in patients with no urine, patients with hepatic coma or hepatic coma, patients with hypoxia, hypovolemia, hypokalemia or hyponatremia who have allergies to this product or sulfonylureas, severe dysuria (such as Prostate hypertrophy) patients disabled this product.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201883007470633.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2017-10-20
附件:
201883007470633.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com